Peeved Bayer to USTR: Indian govt picking winners
This article was originally published in Scrip
Executive Summary
The Indian Nexavar (sorafenib tosylate) compulsory licensing case is still pressing on a raw nerve with Bayer and the German multinational is clearly very peeved with India's handling of intellectual property rights (IPR)-related issues.